Katherine Xu

Katherine Xu

+1 212 237 2758
Email vCard

Specialties:  Biotechnology

Y. Katherine Xu, Ph.D., partner, joined William Blair & Company in March 2011 as a biotechnology analyst. Ms. Xu previously was senior vice president and senior biotechnology analyst at Wedbush Securities, vice president and senior biotechnology analyst at Credit Suisse, and a senior biotechnology analyst at Pacific Growth Equities. Ms. Xu was recognized by the Financial Times/StarMine “World’s Top Analysts” listing, ranking No. 7 overall for stock-picking in the United States in 2010, and No. 2 for stock-picking in biotechnology in 2011; she received the No. 2 ranking in The Wall Street Journal’s “Best on the Street” listing in 2011 as well. Before her move to equity research, Ms. Xu worked in investment banking for two years. Ms. Xu holds a Ph.D. in developmental biology and a Ph.D. minor in engineering-economic systems and operations research from Stanford University Schools of Medicine and Engineering, respectively, and worked on a postdoctoral project in bioinformatics at the Department of Mathematics, Stanford University. She attended Peking University in Beijing and Kalamazoo College in Michigan, where she gained her B.A. with honors.

NuCana plc: Initiation of Research Coverage

William Blair & Company initiated research coverage of NuCana plc (NCNA $14.38). NuCana was founded on ProTide technology, a proprietary platform that converts nucleoside-based chemotherapy agents into protected and pre-activated nucleotides. Learn More

BeiGene, Ltd.: Initiation of Research Coverage

William Blair & Company initiated research coverage of BeiGene, Ltd. (BGNE $36.75), a China-based biotechnology company focused on the research and development of cancer therapies. Learn More

Athersys, Inc.: Initiation of Research Coverage

William Blair & Company initiated research coverage of Athersys, Inc. (ATHX $1.15), a leader in the development of regenerative medicines. Learn More